



# STANFORD VIROLOGY LABORATORY

STANFORD UNIVERSITY MEDICAL CENTER  
3375 HILLVIEW AVE. PALO ALTO, CALIFORNIA 94304  
TEL #: (650) 498-5575 FAX #: (650) 723-6918  
Benjamin Pinsky, M.D., Ph.D. – Director

Patient: **SAMPLE REPORT**

Pathology No: **SHV-14-XXXXX**

Med. Rec. No.:  
Sex: Age:  
Date of Birth: X/X/XXXX  
Account No.:

Date of Procedure: 2/21/2014 5:37:00 PM  
Date Received: 2/21/2014 8:46:00 PM

Physician(s):  
**PHYSICIAN NAME**  
**(CSXXXX)**  
ORDERING FACILITY ADDRESS  
XX STREET  
USA CITY, ST ZIP

## TESTING PERFORMED:

HIV-1 INTEGRASE RESISTANCE

## DIAGNOSIS:

Sequence includes IN codons: 1 - 288  
There are no insertions or deletions  
Subtype: B  
No. previous patient sequences: IN: 0

Major Resistance Mutations None  
Accessory Mutations L74I  
Other Mutations D6E, S17N, E35Q, S39N, M50I, L101I, I135IV,  
G163E, V201I, E212A, R269K

	Integrase Inhibitors
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

IN Comments  
None

Daniel Arber, M.D. – Medical Director



# STANFORD VIROLOGY LABORATORY

STANFORD UNIVERSITY MEDICAL CENTER  
3375 HILLVIEW AVE. PALO ALTO, CALIFORNIA 94304  
TEL #: (650) 498-5575 FAX #: (650) 723-6918  
Benjamin Pinsky, M.D., Ph.D. – Director

Patient: **SAMPLE REPORT**

Pathology No: **SHV-14-XXXXX**

## IN Mutation Scores

	DTG	EVG	RAL
Total	0	0	0

Previous IN sequences from the same patient  
None

---

### The Genotypic Antiretroviral Resistance

Test reports mutations in HIV-1 integrase. Mutations are defined as differences from the wildtype consensus B reference sequence. The interpretation is based on published data in the scientific and medical literature linking mutations and combinations of mutations to phenotypic and clinical drug resistance. The report should be used in conjunction with a patient's clinical history (including past treatments) and with a solid understanding of the principles of antiretroviral treatment (<http://www.aidsinfo.nih.gov/guidelines/>).

A more detailed description of the test interpretation, which includes the consensus B integrase sequence, all of the mutation scores, all of the mutation comments, and updates can be found on the Stanford HIV Drug Resistance Database  
<http://hivdb.stanford.edu/pages/asi/releaseNotes/>.

This test was developed and its performance characteristics determined by the Stanford Clinical Virology Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. Such approval is not required for tests validated by the performing laboratory.

Results Entry  
EMPLOYEE NAME

Electronically signed 2/28/2014 3:38 PM

Daniel Arber, M.D. – Medical Director